文献速递泌尿男性生殖肿瘤

奥拉帕利联合阿比特龙治疗转移性去势抵抗性前列腺癌:随机双盲安慰剂对照2期试验

Olaparib combined with abiraterone in patients with metastatic castration-resistant prostate cancer: a randomised, double-blind, placebo-controlled, phase 2 trial.
PubMed 文献 · Lancet Oncol · 2018-06-04

联合组3级及以上不良事件更常见(54% vs 28%),包括贫血、肺炎和心肌梗死。

要点

  • 联合组3级及以上不良事件发生率为54%,高于对照组的28%,贫血最常见。
  • 联合组发生1例治疗相关死亡(肺炎)。

核心结论

  • 奥拉帕利联合阿比特龙较阿比特龙单药为转移性去势抵抗性前列腺癌患者带来临床疗效获益。
  • 联合组严重不良事件多于单药组,提示需关注安全性。

研究设计与样本

  • 双盲、随机、安慰剂对照2期试验,在欧洲和北美11国41个泌尿肿瘤中心开展。
  • 纳入既往接受过多西他赛且适合阿比特龙治疗的转移性去势抵抗性前列腺癌男性患者(≥18岁)。
  • 排除既往化疗超过2线或曾暴露于第二代抗雄激素药物的患者。
  • 按1:1随机分配至口服奥拉帕利300 mg每日两次或安慰剂,所有患者均接受口服阿比特龙1000 mg每日一次及泼尼松/泼尼松龙5 mg每日两次。
  • 主要终点为研究者评估的影像学无进展生存期(rPFS),基于RECIST 1.1和PCWG2标准;意向治疗人群142例(奥拉帕利组71例,安慰剂组71例)。

主要发现

  • 最常见1-2级不良事件:恶心(奥拉帕利组26例[37%] vs 安慰剂组13例[18%])、便秘(18例[25%] vs 8例[11%])、背痛(17例[24%] vs 13例[18%])。
  • 3级及以上不良事件:奥拉帕利组38例(54%) vs 安慰剂组20例(28%),包括贫血(15例[21%] vs 0例)、肺炎(4例[6%] vs 3例[4%])、心肌梗死(4例[6%] vs 0例)。
  • 严重不良事件:奥拉帕利组24例(34%) vs 安慰剂组13例(18%);奥拉帕利组发生1例治疗相关死亡(肺炎)。

临床怎么用

  • 对于既往多西他赛治疗后的转移性去势抵抗性前列腺癌患者,可考虑奥拉帕利联合阿比特龙以延长rPFS。
  • 联合治疗时需密切监测贫血、肺炎和心肌梗死等不良事件。

局限性

  • 本研究为2期试验,样本量较小(142例),需进一步3期试验验证。
  • 未按HRR突变状态分层,HRR突变状态与疗效的关系未报告。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Patients with metastatic castration-resistant prostate cancer and homologous recombination repair (HRR) mutations have a better response to treatment with the poly(ADP-ribose) polymerase inhibitor olaparib than patients without HRR mutations. Preclinical data suggest synergy between olaparib and androgen pathway inhibitors. We aimed to assess the efficacy of olaparib plus the androgen pathway inhibitor abiraterone in patients with metastatic castration-resistant prostate cancer regardless of HRR mutation status. METHODS: We carried out this double-blind, randomised, placebo-controlled phase 2 trial at 41 urological oncology sites in 11 countries across Europe and North America. Eligible male patients were aged 18 years or older with metastatic castration-resistant prostate cancer who had previously received docetaxel and were candidates for abiraterone treatment. Patients were excluded if they had received more than two previous lines of chemotherapy, or had previous exposure to second-generation antihormonal drugs. Patients were randomly assigned (1:1) using an interactive voice or web response system, without stratification, to receive oral olaparib 300 mg twice daily or placebo. All patients received oral abiraterone 1000 mg once daily and prednisone or prednisolone 5 mg twice daily. Patients and investigators were masked to treatment allocation. The primary endpoint was investigator-assessed radiographic progression-free survival (rPFS; based on Response Evaluation Criteria in Solid Tumors version 1.1 and Prostate Cancer Clinical Trials Working Group 2 criteria). Efficacy analyses were done in the intention-to-treat population, which included all randomly assigned patients, and safety analyses included all patients who received at least one dose of olaparib or placebo. This trial is registered with ClinicalTrials.gov, number NCT01972217, and is no longer recruiting patients. FINDINGS: Between Nov 25, 2014, and July 14, 2015, 171 patients were assessed for eligibility. Of those, 142 patients were randomly assigned to receive olaparib and abiraterone (n=71) or placebo and abiraterone (n=71). The clinical cutoff date for the final analysis was Sept 22, 2017. Median rPFS was 13·8 months (95% CI 10·8-20·4) with olaparib and abiraterone and 8·2 months (5·5-9·7) with placebo and abiraterone (hazard ratio [HR] 0·65, 95% CI 0·44-0·97, p=0·034). The most common grade 1-2 adverse events were nausea (26 [37%] patients in the olaparib group vs 13 [18%] patients in the placebo group), constipation (18 [25%] vs eight [11%]), and back pain (17 [24%] vs 13 [18%]). 38 (54%) of 71 patients in the olaparib and abiraterone group and 20 (28%) of 71 patients in the placebo and abiraterone group had grade 3 or worse adverse events, including anaemia (in 15 [21%] of 71 patients vs none of 71), pneumonia (four [6%] vs three [4%]), and myocardial infarction (four [6%] vs none). Serious adverse events were reported by 24 (34%) of 71 patients receiving olaparib and abiraterone (seven of which were related to treatment) and 13 (18%) of 71 patients receiving placebo and abiraterone (one of which was related to treatment). One treatment-related death (pneumonitis) occurred in the olaparib and abiraterone group. INTERPRETATION: Olaparib in combination with abiraterone provided clinical efficacy benefit for patients with metastatic castration-resistant prostate cancer compared with abiraterone alone. More serious adverse events were observed in patients who received olaparib and abiraterone than abiraterone alone. Our data suggest that the combination of olaparib and abiraterone might provide an additional clinical benefit to a broad population of patients with metastatic castration-resistant prostate cancer. FUNDING: AstraZeneca.

来源:Lancet Oncol,查看原文。版权归原作者所有。

引用

  1. Clarke N, Wiechno P, Alekseev B, et al. Olaparib combined with abiraterone in patients with metastatic castration-resistant prostate cancer: a randomised, double-blind, placebo-controlled, phase 2 trial. Lancet Oncol. 2018. PMID: 29880291. doi:10.1016/S1470-2045(18)30365-6

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。